Minerva Imaging is a scientifically driven CRO founded in 2011. Our focus is on the use of advanced oncology models and molecular imaging for translational cancer research and drug development. We engage with our clients to understand their scientific questions and discuss how our methods and capabilities can provide answers. Our competences build on more than two decades of research within oncology and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.
Building on more than two decades of research in Nuclear Medicine we are proficient in conducting molecular imaging studies with a translational focus.
Imaging studies can be combined with our advanced oncology models to investigate the in vivo biodistribution, e.g. radiolabeled antibodies, or imaging biomarkers in drug efficacy studies.
We facilitate clinical translation (Phase I/II) of radio-tracers in collaboration with our clinical partners.
18F-FDG, 18F-FLT, 18F-FET, 18F-NaF, 18F-FES
89Zr labeled antibodies, e.g. 89Zr-trastuzumab
Custom radiolabeling of small molecules, peptides, proteins and antibodies using e.g. 89Zr.
Optical (bioluminescence) imaging
We have extensive experience in design and execution of pre-clinical studies for drug development within oncology and immuno-oncology. We can perform studies with cell line based models as well as PDX models available through the START-MINERVA collaboration. Studies can be designed to take advantage of our capabilities of orthotopic and metastatic models, external radiation therapy, and advanced non-invasive imaging.
We have a strong focus on imaging of pathophysiology in cardiovascular disease. Using relevant animals models of cardiovascular disease and longitudinal study designs we can follow therapeutic interventions by non-invasive imaging. Studies can be designed to take advantage of in-depth capabilities of microsurgery to establish e.g. myocardial infarction and ischemia-reperfusion models in rodents and larger species. Also, we have a long track record of using PET/CT imaging to monitor vascular inflammation in atherosclerosis.
Patient Derived Xenograft (PDX) Services
We have substantial experience in performing studies with targeted radionuclide therapy in oncology. Our capabilities include testing of alpha- as well as beta-emitting ligands in subcutaneous, orthotropic or metastatic cancer models.
We facilitate clinical translation into Phase I studies including clinical trial design and execution in collaboration with our clinical partners.
"We are very pleased with the quality of their services, their customer service and their flexibility."
Minerva Imaging ApS has not received any endorsements.